Labrini Papanastasiou
Overview
Explore the profile of Labrini Papanastasiou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
311
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mytareli C, Kalotychou V, Lafioniatis A, Kaltsas G, Zografos G, Markou A, et al.
Front Endocrinol (Lausanne)
. 2025 Feb;
16:1511520.
PMID: 39950028
Introduction: Adrenal tumors (ATs) encompass a wide differential diagnosis, necessitating a multi-step process for accurate identification. Liquid biopsy emerges as a promising non-invasive technique for distinguishing between malignant and benign,...
2.
Thodou E, Choreftaki T, Kounadi T, Papanastasiou L, Kontogeorgos G
Cureus
. 2022 Sep;
14(8):e28423.
PMID: 36176816
Head and neck paragangliomas (PGLs) most commonly derive from the carotid body, jugulotympanic, vagal, and laryngeal paraganglia. Thyroid PGLs originate in the inferior laryngeal paraganglion, which may lie inside the...
3.
Tyfoxylou E, Voulgaris N, Gravvanis C, Vlachou S, Markou A, Papanastasiou L, et al.
Biomedicines
. 2022 Sep;
10(9).
PMID: 36140406
Primary aldosteronism (PA) is the most common cause of endocrine hypertension. The prevalence of hypertension is higher in patients with diabetes mellitus-2 (DM-2). Following the limited existing data, we prospectively...
4.
Fountas A, Kanti G, Glycofridi S, Christou M, Kalantzi A, Giagourta I, et al.
Endocrine
. 2022 Sep;
78(3):570-579.
PMID: 36074243
Purpose: Pheochromocytomas are rare tumors and biochemically silent ones with normal catecholamine levels are even rarer. Up to date, biochemically inactive pheochromocytomas are poorly investigated. We aimed to systematically assess...
5.
Papanastasiou L, Skarakis N, Vardaka M, Dimitriadi A, Lampropoulou P, Perpinia A, et al.
Leuk Res Rep
. 2022 May;
17:100318.
PMID: 35539018
We report an extremely rare case of extranodal B-cell NHL: DLBCL (diffuse large B-cell non-Hodgkin lymphoma), stage IVE, presenting with heart and bilateral adrenal involvement. On admission, adrenal and thorax...
6.
Skarakis N, Papadimitriou I, Papanastasiou L, Pappa S, Dimitriadi A, Glykas I, et al.
Endocrinol Diabetes Metab Case Rep
. 2022 Jan;
2022.
PMID: 35023474
Summary: Juxtaglomerular cell tumour (JGCT) is an unusually encountered clinical entity. A 33-year-old man with severe long-standing hypertension and hypokalaemia is described. The patient also suffered from polyuria, polydipsia, nocturia...
7.
Markou A, Kaltsas G, Papanastasiou L, Gravvanis C, Voulgaris N, Kanti G, et al.
Eur J Endocrinol
. 2021 Dec;
186(2):265-273.
PMID: 34882580
Objective: Primary aldosteronism (PA) is the commonest cause of endocrine hypertension ranging from 4.6 to 16.6% according to the diagnostic tests employed. The aim of this study was to compare...
8.
Gravvanis C, Papanastasiou L, Glycofridi S, Voulgaris N, Tyfoxylou E, Theodora K, et al.
Hormones (Athens)
. 2021 Sep;
20(4):793-802.
PMID: 34524646
Introduction: Increased prevalence of hyperparathyroidism (HP) has been observed in primary aldosteronism (PA) patients. However, HP prevalence in milder forms of PA has not to date been evaluated. Objectives: The...
9.
Voulgaris N, Tyfoxylou E, Vlachou S, Kyriazi E, Gravvanis C, Kapsali C, et al.
Horm Metab Res
. 2021 Jul;
53(7):461-469.
PMID: 34282597
Primary aldosteronism (PA) is the most common endocrine cause of arterial hypertension. Despite the increasing incidence of hypertension worldwide, the true prevalence of PA in hypertension was only recently recognized....
10.
Efstathiadou Z, Tsentidis C, Bargiota A, Daraki V, Kotsa K, Ntali G, et al.
Eur Thyroid J
. 2021 May;
10(2):125-139.
PMID: 33981617
Introduction: Tyrosine kinase inhibitors (TKIs) have been used in patients with advanced medullary thyroid carcinoma (MTC); however, data on their effectiveness and safety are limited. The aim of this systematic...